Naturally Splendid Enterprises is currently identifying multiple opportunities emerging from the recently acquired access to technologies from FSL Laboratories (FSL).
Naturally Splendid CEO Craig Goodwin reports, “One of the opportunities in front of us is the potential to biosynthetically produce pharmaceutical grade cannabinoids without having to grow a single plant and thus potentially lowering the cost of production significantly, creating a competitive advantage over traditional extraction and formulation technologies. This technology may be applied in the development of food, beverage and nutraceutical/cosmetic products and eventually for pharmaceutical applications.”
Naturally Splendid VP of Operations Bryan Carson reports, “There is no better way to advance these opportunities than to retain key personal within Boreal to assist us in driving multiple revenue opportunities. This is further proof of the existing and in fact, the continued strengthening of the relationship between FSL / Boreal and Naturally Splendid.”
Ms. Katie Schmitt, from Boreal Technologies will be directly involved in the transfer of technological expertise obtained under the agreement from FSL and implementation of commercialization strategies.
She reports, “FSL has filed a patent application covering the organic and enzymatic synthesis of cannabinoids. This technology will allow for industrial scale production of cannabinoids catalyzed from Cannbigerolic acid (CBGa) without the requirement to grow large quantities of plants. The process mimics the natural synthesis that occurs in the plant’s bio-pathway. Cannabinoids produced in the bioreactor are pharmaceutical grade purity (>99%) and devoid of by-products and impurities. The largest advantages with this technology over existing methods of cannabinoid production (natural and synthetic) are: its low price per unit manufacturing costs (potentially 1/10th to 1/3rd the cost of existing methods); its ability to produce a diversity of products from a single manufacturing line; and commercial scalability. It also creates access to lesser known cannabinoids for research and analysis of their potential therapeutic applications.
NSP will identify licensed partners in legal jurisdictions that it can collaborate with to develop safe and efficacious cannabinoid therapies utilizing this technology. Potential therapeutic applications include: Analgesic to relieve pain; Antibacterial to slow bacterial growth; Anti-inflammatory to reduce inflammation systemically; and Anti-Proliferative – which may inhibit cancer cell growth through apoptosis.
